NEW YORK, April 16 - Arradial, a spin-off of Alexion Pharmaceuticals that develops microfluidic-based microarray technology, today said it has secured $3 million in additional Series A financing from Oxford Bioscience Partners.
The company, based in Bedford, Mass., is also expected to announce tomorrow the appointment of John R. Havens as senior vice president of technology. Havens, who comes to Arradial from Nanogen, where he was senior director for chemistry and high-throughput screening, will help the firm develop and commercialize its microfluidics technology.
Yesterday, Arradial hired Mark A. Tepper president and CEO. Tepper was previously vice president for research and operations at the Serono Pharmaceutical Research Institute.